skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience

Abstract

Purpose: To collect response rates of primary cutaneous anaplastic large cell lymphoma, a rare cutaneous T-cell lymphoma, to radiation therapy (RT), and to determine potential prognostic factors predictive of outcome. Methods and Materials: The study was a retrospective analysis of patients with primary cutaneous anaplastic large cell lymphoma who received RT as primary therapy or after surgical excision. Data collected include initial stage of disease, RT modality (electron/photon), total dose, fractionation, response to treatment, and local recurrence. Radiation therapy was delivered at 8 participating International Lymphoma Radiation Oncology Group institutions worldwide. Results: Fifty-six patients met the eligibility criteria, and 63 tumors were treated: head and neck (27%), trunk (14%), upper extremities (27%), and lower extremities (32%). Median tumor size was 2.25 cm (range, 0.6-12 cm). T classification included T1, 40 patients (71%); T2, 12 patients (21%); and T3, 4 patients (7%). The median radiation dose was 35 Gy (range, 6-45 Gy). Complete clinical response (CCR) was achieved in 60 of 63 tumors (95%) and partial response in 3 tumors (5%). After CCR, 1 tumor recurred locally (1.7%) after 36 Gy and 7 months after RT. This was the only patient to die of disease. Conclusions: Primary cutaneous anaplastic large cell lymphoma is a rare, indolent cutaneous lymphomamore » with a low death rate. This analysis, which was restricted to patients selected for treatment with radiation, indicates that achieving CCR was independent of radiation dose. Because there were too few failures (<2%) for statistical analysis on dose response, 30 Gy seems to be adequate for local control, and even lower doses may suffice.« less

Authors:
 [1]; ; ;  [1];  [2];  [3];  [4];  [5];  [6];  [7];  [8];  [1]
  1. Stanford Cancer Institute, Stanford, California (United States)
  2. Department of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne (Australia)
  3. The University of Texas MD Anderson Cancer Center, Houston, Texas (United States)
  4. Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario (Canada)
  5. Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (United States)
  6. Department of Therapeutic Radiology/Radiation Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, Connecticut (United States)
  7. Department of Oncology, University of Turin, Turin (Italy)
  8. Institut Curie, Paris (France)
Publication Date:
OSTI Identifier:
22648764
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 95; Journal Issue: 5; Other Information: Copyright (c) 2016 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; GY RANGE 01-10; GY RANGE 10-100; LYMPHOMAS; PATIENTS; RADIATION DOSES; RADIOTHERAPY

Citation Formats

Million, Lynn, E-mail: lmillion@stanford.edu, Yi, Esther J., Wu, Frank, Von Eyben, Rie, Campbell, Belinda A., Dabaja, Bouthaina, Tsang, Richard W., Ng, Andrea, Wilson, Lynn D., Ricardi, Umberto, Kirova, Youlia, and Hoppe, Richard T. Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience. United States: N. p., 2016. Web. doi:10.1016/J.IJROBP.2016.03.023.
Million, Lynn, E-mail: lmillion@stanford.edu, Yi, Esther J., Wu, Frank, Von Eyben, Rie, Campbell, Belinda A., Dabaja, Bouthaina, Tsang, Richard W., Ng, Andrea, Wilson, Lynn D., Ricardi, Umberto, Kirova, Youlia, & Hoppe, Richard T. Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience. United States. doi:10.1016/J.IJROBP.2016.03.023.
Million, Lynn, E-mail: lmillion@stanford.edu, Yi, Esther J., Wu, Frank, Von Eyben, Rie, Campbell, Belinda A., Dabaja, Bouthaina, Tsang, Richard W., Ng, Andrea, Wilson, Lynn D., Ricardi, Umberto, Kirova, Youlia, and Hoppe, Richard T. Mon . "Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience". United States. doi:10.1016/J.IJROBP.2016.03.023.
@article{osti_22648764,
title = {Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience},
author = {Million, Lynn, E-mail: lmillion@stanford.edu and Yi, Esther J. and Wu, Frank and Von Eyben, Rie and Campbell, Belinda A. and Dabaja, Bouthaina and Tsang, Richard W. and Ng, Andrea and Wilson, Lynn D. and Ricardi, Umberto and Kirova, Youlia and Hoppe, Richard T.},
abstractNote = {Purpose: To collect response rates of primary cutaneous anaplastic large cell lymphoma, a rare cutaneous T-cell lymphoma, to radiation therapy (RT), and to determine potential prognostic factors predictive of outcome. Methods and Materials: The study was a retrospective analysis of patients with primary cutaneous anaplastic large cell lymphoma who received RT as primary therapy or after surgical excision. Data collected include initial stage of disease, RT modality (electron/photon), total dose, fractionation, response to treatment, and local recurrence. Radiation therapy was delivered at 8 participating International Lymphoma Radiation Oncology Group institutions worldwide. Results: Fifty-six patients met the eligibility criteria, and 63 tumors were treated: head and neck (27%), trunk (14%), upper extremities (27%), and lower extremities (32%). Median tumor size was 2.25 cm (range, 0.6-12 cm). T classification included T1, 40 patients (71%); T2, 12 patients (21%); and T3, 4 patients (7%). The median radiation dose was 35 Gy (range, 6-45 Gy). Complete clinical response (CCR) was achieved in 60 of 63 tumors (95%) and partial response in 3 tumors (5%). After CCR, 1 tumor recurred locally (1.7%) after 36 Gy and 7 months after RT. This was the only patient to die of disease. Conclusions: Primary cutaneous anaplastic large cell lymphoma is a rare, indolent cutaneous lymphoma with a low death rate. This analysis, which was restricted to patients selected for treatment with radiation, indicates that achieving CCR was independent of radiation dose. Because there were too few failures (<2%) for statistical analysis on dose response, 30 Gy seems to be adequate for local control, and even lower doses may suffice.},
doi = {10.1016/J.IJROBP.2016.03.023},
journal = {International Journal of Radiation Oncology, Biology and Physics},
number = 5,
volume = 95,
place = {United States},
year = {Mon Aug 01 00:00:00 EDT 2016},
month = {Mon Aug 01 00:00:00 EDT 2016}
}